LLY Q3 2026 Earnings Analysis
Eli Lilly reported 39% Q3 revenue growth driven by strong Mounjaro/Zepbound uptake and Medicare GLP-1 bridge program success, raising FY 2026 guidance to $91-92B revenue and $35-36 EPS.
Key Metrics
Puntos clave
- Q3 revenue grew 39% YoY driven by Mounjaro/Zepbound momentum; combined product revenue exceeded $16 billion.
- Medicare GLP-1 bridge expanded obesity access to 20M seniors; 500K+ prescriptions filled since July 1 launch.
- Raised FY 2026 guidance to $91-92B revenue and $35-36 EPS reflecting strong portfolio performance.
Escuchar en
Disponible en
Transcript
// Full episode scriptWelcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex, joined as always by Jordan, and today we're digging into Eli Lilly's Q3 2026 results — and folks, this is a big one.
Huge one. Stock popped over 6.5% on the news.
It really did. But before we get into it — quick disclaimer. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
Important stuff. Okay, Alex, let's talk numbers because they're staggering.
Revenue grew 39% year-over-year — that's nearly $7 billion in additional revenue in a single quarter. Non-GAAP EPS came in at $7.48, and gross margin actually expanded to 84.4%.
And the guidance raise is what really got everyone's attention. Full-year revenue guidance moved up to $91-92 billion, and EPS guidance jumped to $35-36 — that's roughly a $4 per share increase at the midpoint from where they were tracking before.
Which is wild because this isn't the first raise this year. CFO Lucas Montarce basically said they've now raised full-year revenue guidance by about $10 billion since the start of 2026.
And when analysts pushed on that — like, "are you guys just being too conservative?" — CEO David Ricks had a great answer. He basically said, look, we're in the middle of the largest category expansion in pharma history. There's real uncertainty here, and he'd rather beat estimates than miss them. Two big unknowns this year were the Medicare bridge program uptake and how deep international out-of-pocket demand would go — and both surprised to the upside.
Let's talk about that Medicare bridge program because it's honestly the story of the quarter. This opened up obesity medicine access to about 20 million seniors starting July 1st, and in just one quarter, over half a million people already filled a prescription.
And Lilly is absolutely dominating that channel — 7 out of 10 new bridge patients are starting on a Lilly medicine. There was even a USC Schaeffer Center study cited saying this program could save Medicare over $20 billion cumulatively over ten years. That's a pretty powerful argument for why this program might get extended or made permanent.
Right, and that was actually a direct question in the Q&A — will this bridge program survive past 2026? Ricks sounded genuinely optimistic, citing strong uptake, appropriate use based on BMI and comorbidities, and that cost-effectiveness data. He thinks it could get folded into the permanent Part D benefit going forward.
Let's not overlook the core business though — Mounjaro and Zepbound combined for over $16 billion in the quarter alone, contributing $6 billion of year-over-year growth. China was a standout too — Mounjaro became the first medicine there ever to cross $1 billion in its first full year, with 62% constant currency growth.
And it's not just incretins anymore. Management specifically called out that oncology, immunology, and neuroscience revenue combined actually doubled year-over-year. Jaypirca up 59%, Ebglyss up 59%, and Kisunla — their Alzheimer's drug — up a staggering 175%.
That diversification story matters. David Ricks made a point of saying three-fourths of their clinical pipeline is actually outside of obesity. They don't want to be a one-trick pony, even though the trick is working extremely well right now.
Speaking of the pipeline, there was some really juicy data this quarter. Retatrutide — their triple agonist — went head-to-head with semaglutide in type 2 diabetics and basically more than doubled the weight loss, 20-21% versus 9.4%.
And then there's this combo drug, Olora-TZP — combining amylin agonism with tirzepatide — hit 23% weight loss at 48 weeks, plus some diabetics got their A1C down to near-normal levels. The high dose had tolerability issues, but they're already planning a gentler escalation for Phase 3.
Oh, and Foundayo — their oral GLP-1 — is scaling fast. Nearly 4 in 10 new oral obesity patients are choosing it now, and it's live in four countries outside the US with over 40 more under review. Type 2 diabetes approval in the US is expected by year-end too.
On the capital side, they're putting real money behind manufacturing — broke ground on a $6.5 billion facility in Houston and a $5 billion one in Richmond, Virginia. That's a serious long-term supply bet.
They're clearly preparing for sustained demand, not a sugar high. One thing I want to flag for listeners — management was upfront that 2026 revenue got a boost from about $2 billion in one-time items, milestone payments and rebate estimate changes, that won't repeat in 2027. So don't just extrapolate this growth rate blindly.
Good catch. Pricing is also worth watching — US net price declined, and management expects pricing to remain a headwind next year too, just offset by continued volume growth. The mix shift toward Medicare and Medicaid could pressure average net price per prescription even as the overall pie keeps growing.
So bottom line for investors — Lilly's incretin dominance is still intact, international demand is clearly deeper than people expected, the Medicare bridge program is a potential game-changer for both the company and seniors, and the pipeline behind obesity — oncology, neuroscience, immunology — is quietly becoming a second growth engine.
Before we wrap, a reminder: everything discussed is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence.
Well said. Lilly's got their big Investor Day coming up December 7th, which should give us even more color on the pipeline. We'll be back to break that down when it happens.
Until then, thanks for tuning in to Beta Finch!
See you next time!